Yibo Xue

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9217477/publications.pdf

Version: 2024-02-01

		1040056	1474206	
9	460	9	9	
papers	citations	h-index	g-index	
10 all docs	10 docs citations	10 times ranked	810 citing authors	

#	Article	IF	CITATIONS
1	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications, 2019, 10, 557.	12.8	125
2	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Research, 2020, 80, 444-457.	0.9	88
3	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 2019, 10, 558.	12.8	76
4	The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. Nature Cancer, 2021, 2, 1357-1371.	13.2	55
5	SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Research, 2015, 25, 445-458.	12.0	36
6	elF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. Molecular Cancer Therapeutics, 2019, 18, 2158-2170.	4.1	25
7	Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. ELife, 2021, 10 , .	6.0	23
8	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria. Nature Communications, 2021, 12, 5404.	12.8	20
9	<scp>SMARCB1</scp> loss induces druggable cyclin <scp>D1</scp> deficiency via upregulation of <scp><i>MIR17HG</i></scp> in atypical teratoid rhabdoid tumors. Journal of Pathology, 2020, 252, 77-87.	4.5	11